IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

Rhea-AI Summary

IGC Pharma announced that CEO Ram Mukunda and CCO Claudia Grimaldi will participate in a fireside chat hosted by Ascendiant Capital Markets on June 27, 2024, at 12:00 pm ET. They will discuss recent achievements and upcoming milestones. IGC Pharma focuses on developing treatments for Alzheimer's disease with a pipeline that includes five drug candidates. Notably, IGC-AD1 is in Phase 2 clinical trials targeting agitation in dementia associated with Alzheimer's, while other candidates like TGR-63, IGC-M3, and IGC-1C are in preclinical stages. The company also leverages AI for Alzheimer's research.

Positive

• CEO and CCO participating in a fireside chat, potentially increasing investor engagement.
• IGC-AD1 in Phase 2 clinical trials for agitation in dementia associated with Alzheimer's.
• Diverse pipeline with five drug candidates targeting Alzheimer's disease.
• Leverage of AI for optimizing clinical trials and early detection of Alzheimer's.

Negative

• Most drug candidates are still in preclinical stages, indicating a long road to market.
• No revenue or financial performance details provided.
• Potential shareholder dilution or fundraising needs not addressed.

POTOMAC, Md.--(BUSINESS WIRE)-- IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Thursday, June 27, 2024, at 12:00 pm ET. IGC Pharma management will discuss recent operational achievements as well as upcoming milestones.

To register and join the fireside chat visit:
https://events.zoom.us/ev/ArQg-ZdS6F17yH0Me0ShSdoDCre7Pt9nHvcyTxBN-xMPhKgKCq2T~AiJBXagKRgilw_LG-3dX1ni73kTj4cxNoYrUyVBuB6VDsbC2PJD9KILpuA.

About IGC Pharma, Inc.

IGC Pharma Inc. (“IGC”) is focused on Alzheimer’s disease, developing innovative solutions to address this devastating illness. The Company’s mission is to transform the landscape of Alzheimer’s treatment with a robust pipeline of five promising drug candidates. IGC-AD1 and LMP target the hallmarks of Alzheimer’s disease, including neuroinflammation, Aβ plaques, and neurofibrillary tangles. IGC-AD1 is currently undergoing a Phase 2 clinical trial for agitation in dementia associated with Alzheimer’s (clinicaltrials.gov, NCT05543681). TGR-63 disrupts the progression of Alzheimer’s by targeting Aβ plaques. IGC-M3, currently in preclinical development, aims to inhibit the aggregation of Aβ plaques, potentially impacting early-stage Alzheimer’s. IGC-1C, also in preclinical stages, targets tau protein and neurofibrillary tangles, representing a forward-thinking approach to Alzheimer’s therapy. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (“AI”) for Alzheimer’s research. Their AI projects encompass various areas, including clinical trial optimization and early detection of Alzheimer’s.

Forward-looking Statements

This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma’s U.S. Securities and Exchange Commission (“SEC”) filings. IGC Pharma incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on July 7, 2023, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240618553406/en/

Investors

IMS Investor Relations

Walter Frank/Rosalyn Christian

igc@imsinvestorrelations.com

(203) 972-9200

Media

JVPRNY

Janet Vasquez

jvasquez@jvprny.com

(212) 645-5498

Source: IGC Pharma, Inc.

FAQ

When is IGC Pharma's fireside chat with Ascendiant Capital Markets?

The fireside chat is scheduled for June 27, 2024, at 12:00 pm ET.

What will be discussed in IGC Pharma's fireside chat?

The chat will cover recent operational achievements and upcoming milestones.

What is IGC-AD1?

IGC-AD1 is a drug candidate in Phase 2 clinical trials targeting agitation in dementia associated with Alzheimer's disease.

What stage are IGC Pharma's other drug candidates in?

Most of the other drug candidates, including TGR-63, IGC-M3, and IGC-1C, are in preclinical stages.

How does IGC Pharma leverage AI in Alzheimer's research?

IGC Pharma uses AI to optimize clinical trials and aid in the early detection of Alzheimer's disease.